San Diego biotech Trovagene Inc. has a new board member known for her expertise in the clinical development of oncology therapeutics.

The cancer test company announced Sept. 20 that Dr. Athena Countouriotis was appointed to its board of directors.

Countouriotis is currently the senior vice president, chief medical officer at Adverum Biotechnologies, which is based in Menlo Park, California. Before joining Adverum, she was senior vice president and chief medical officer at Halozyme Therapeutics in San Diego.

Trovagene said Countouriotis has extensive experience leading clinical development programs, from preclinical through clinical stages, as well as approval. The clinical programs she’s been involved in had a focus in oncology -- both hematologic and solid tumor indications -- that supported regulatory approvals in the U.S. and Europe.

She holds a doctor of medicine from Tufts University School of Medicine, completed her pediatric residency at the University of California Los Angeles, and completed additional training at Fred Hutchinson Cancer Research Center in the pediatric hematology-oncology program.